Researchers at the German Red Cross Blood Donor Service in Frankfurt headed by Professor Erhard Seifried, and the Institute for Medical Virology at the University Hospital Frankfurt at Goethe University headed by Professor Sandra Ciesek succeeded in developing a procedure that makes it possible to immediately and dramatically increase worldwide testing capacities for detecting SARS-CoV-2. "This makes it possible for the implementation of expanded testing in larger population groups as demanded by all scientists and also politicians to be carried out sooner than previously thought, even in view of limited test kit resources," says Seifried. The background of this news are laboratory investigations in which swab samples from mucous membranes of the throat or nose are combined using specified procedures in a buffer solution, and subsequently tested using what is known as the PCR procedure (polymerase chain reaction procedure, direct genome detection of SARS CoV-2). In the case of a negative result, all included samples have a reliable negative result. The pool testing has no influence on the detection limit. In the case of a positive mini-pool result, individual testing is carried out in previously reserved samples. The positive sample can then be identified within 4 hours.
Figure 1 shows the new mini-pool method. The swab is first placed in a reserve test tube and subsequently in a pool container. Since this pool method does not increase the volume in the pool container, no dilution and therefore no decrease in sensitivity is observed. Using independent ring trial samples (pre-test of the planned ring trial), that were provided by a ring trial organisation (INSTAND) authorised by the by the German Medical Association, it was able to be shown that the new mini-pool method can obtain laboratory results of equal quality as those obtained with individual testing. The new method was additionally investigated in a small field study on 50 unselected patient samples. The patient samples were pooled in 10 mini-pools of 5 samples each, and also tested individually in parallel. Of the 50 patient samples, 5 samples were SARS CoV-2 positive. These samples were distributed across 4 pools. All four mini-pools resulted in a positive PCR result. Mini-pools containing only samples from patients without SARS CoV-2 always resulted in a negative result.
"On the basis of these laboratory results, in particular large cohorts and testing on asymptomatic individuals can be carried out, allowing a massive savings of test kits in particular," says Ciesek. The research group is currently analysing options for further enlarging the pools. "The results give cause for optimism that when globally established, the procedure will quickly enable better information about the number of people actually infected," explains Professor Schmidt from the Blood Donor Service. This allows the current number of approximately 40,000 tests per day in all of Germany to be immediately increased to 200,000 to 400,000 tests without reducing the high quality of the diagnosis. To continue efficiently implementing the strategy of early detection and isolation, an extension of screening tests is essential, especially for system-relevant professions such as doctors, nurses, police, firefighters, nursing homes, administration and the food industry. The rights to the invention, for which a patent is pending in Europe and the USA, is held jointly by Goethe University and the German Red Cross. The technology can be made available immediately to other interested institutions through Goethe University's knowledge transfer company Innovectis.
Goethe University President Professor Birgitta Wolff describes the new analysis method as a "milestone". "The more people who can be reliably tested for SARS-CoV-2, the faster the pandemic can be curbed."
"With the new method, Germany can take the global fight against SARS-CoV-2 to a new a new level," observes Seifried with optimism. The medical director of the University Hospital Frankfurt, Professor Graf, and the president of Goethe University both stressed the successful and trustful collaboration between the Blood Donor Service, the University Hospital, and Goethe University.
Pictures download: http://www.uni-frankfurt.de/87014427
a) Graphics: Sars-CoV-2: The mini-pool method allows for increasing test capacities to detect the virus with no decrease in sensitivity. Graphcis: Michael Schmidt, German Red Cross Blood Donor Service, Frankfurt Institute
b) Table: Table of external ring trial samples
Professor Dr. med. Dr. h. c. Erhard Seifried (Goethe University)
Medical Managing Director
German Red Cross Blood Donor Service Baden-Wuertemberg - Hessen
Institute of Transfusion Medicine and Immunohaematology
60528 Frankfurt, Germany
Phone: +49 (0)69 / 6782-201
Professor Dr. med. Sandra Ciesek
Institute of Medical Virology
For inquiries please contact:
Public Relations Department, University Clinic Frankfurt am Main, Germany,
Phone. +49 69 6301 6444,
Current news about science, teaching, and society can be found on GOETHE-UNI online (http://www.aktuelles.uni-frankfurt.de)
Goethe University is a research-oriented university in the European financial centre Frankfurt am Main. The university was founded in 1914 through private funding, primarily from Jewish sponsors, and has since produced pioneering achievements in the areas of social sciences, sociology and economics, medicine, quantum physics, brain research, and labour law. It gained a unique level of autonomy on 1 January 2008 by returning to its historic roots as a "foundation university". Today, it is one of the three largest universities in Germany. Together with the Technical University of Darmstadt and the University of Mainz, it is a partner in the inter-state strategic Rhine-Main University Alliance. Internet: http://www.uni-frankfurt.de
Publisher: The President of Goethe University Editor: Dr. Markus Bernards, Science Editor, PR & Communication Department, Theodor-W.-Adorno-Platz 1, 60323 Frankfurt am Main, Tel: -49 (0) 69 798-12498, Fax: +49 (0) 69 798-763 12531, firstname.lastname@example.org.